ClinicalTrials.gg
CompletedNCT05685589Updated Jul 17, 2024

Mindfulness-Based Intervention for Teens With Autism Spectrum Disorder and Their Caregivers

An interventional study of MINDful TIME in Autism Spectrum Disorder, sponsored by Southwest Autism Research & Resource Center. Completed at 1 site in United States. Open to participants aged 13 Years to 18 Years. Per ClinicalTrials.gov, last updated 2024-07-17.

Sponsored by Southwest Autism Research & Resource Center · Not applicable, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
42
Allocation
Randomized
Ages
13 Years to 18 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 773 studies in Autism Spectrum Disorder with a site in United States — 163 open to participants now, 203 under way, 9 of them phase 3. Autism Spectrum Disorder · United States.

Enrollment
367th of 658
42 · median 50
Started
2023
with 56 others
No phase
456 of 773
104 open now
Registered
583rd of 773
by date

Among the 773 studies in Autism Spectrum Disorder with a site in United States, this one is the 367th largest by enrollment of the 658 interventional ones that give a count, is one of 57 that started in 2023, is one of 456 with no phase, and was the 583rd registered.

Autism Spectrum Disorder

1,733 studies on the registry are indexed under Autism Spectrum Disorder; 503 are open to participants now.

Browse Autism Spectrum Disorder studies →

Open to participants now

163 of the 773 studies in Autism Spectrum Disorder with a site in United States are open now. Recruiting first, the newest first:

158 more — sign in →

All 163 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 351 Autism Spectrum Disorder studies recruiting now, 48 (14%) set no upper age limit and 296 (84%) stop at 75 or younger; 301 take children under 18; 92 take healthy volunteers.

This study: 13 Years to 18 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 773 studies in Autism Spectrum Disorder with a site in United States, or all of them as a file.
02

Study summary

This project will evaluate the effectiveness of MINDful TIME, an 8-week mindfulness-based program designed to improve mental health in adolescents with autism spectrum disorder and their caregivers. MINDful TIME includes weekly psychoeducational group meetings conducted through videoconferencing and use of a commercially available mindfulness meditation app. The investigators predict that adolescents in the mindfulness intervention group will demonstrate increases in self-reported mindfulness and reductions in self- and parent-reported anxiety and depression relative to a delayed treatment control group. The investigators will also explore whether caregivers in the treatment group demonstrate improvements in quality of life.

Read the detailed description

Interested individuals and their parent/caregiver who meet preliminary eligibility criteria during the phone screen will be scheduled for a 1-2 hour virtual study visit to complete an intake interview for study and a brief IQ test. If individuals have completed this assessment at SARRC within the last five years, they will not be re-assessed; however, they will complete a 30-minute virtual intake visit to complete the intake interview, learn about the intervention and determine if they would like to participate.

Participants in the treatment group will complete three virtual study visits (Baseline, intervention exit, 2-month follow-up), whereas participants in the delayed treatment control group will complete four virtual study visits (Baseline, wait for the period exit, intervention exit, 2 month-follow-up). After completing their second-time point (i.e., wait period exit) participants in the delayed treatment control group will be enrolled in the 8-week intervention.

The investigators anticipate that the duration of an individual participant's participation in the study from baseline data collection to study completion will be approximately 6 months. Participants may be enrolled up to 8 months prior to their baseline data collection depending on when they are recruited into the study and whether they participate in cohort 1 or cohort 2.

03

Conditions studied

  • Autism Spectrum Disorder
04

Who can participate

Ages eligible
13 Years to 18 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adolescents must be ages 13 to 18 years
  • Formal clinical or educational ASD diagnosis confirmed by the study team (i.e., review of the formal diagnostic or educational report)
  • Must be willing to be randomized to a treatment or delayed treatment control group
  • Must be able to attend at least 7 of the 8 group meetings
  • English speaking: Adolescents and their parent/caregivers must be English-speaking because the screening and behavioral measures are in English, as well as the intervention content
  • Participants must live in the state of Arizona, USA

Exclusion criteria

Exclusion Criteria:

  • Non-verbal participants will be excluded to ensure test compliance and increase sample homogeneity.
  • Participants with IQ scores \<70 will be excluded because the intervention was developed for individuals without intellectual disabilities.
  • Participants with a physical disability or co-occurring condition that may prevent participation in the weekly group meetings (e.g., selective mutism; aggressive behavior; inability to participate in a 90-minute video conference meeting each week)
  • Participants who report active suicidal ideation
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
42 participants (actual)

Study arms

  • Experimental
    Mindfulness-based Intervention

    The intervention will include weekly 90-minute group meetings held online through Zoom. Adolescents and parents will meet in separate groups and will learn about mindfulness-based strategies that can be used to manage and reduce stress, anxiety, and depression. They will also learn evidence-based strategies to complete daily guided mindfulness meditations using Ten Percent Happier, a commercially-available mobile app. Participants will be encouraged to meditate using the mobile app for at least 10 minutes each day during and after the 8-week intervention.

    Behavioral: MINDful TIME

  • No intervention
    Delayed Treatment Control

    Participants will be instructed to engage in treatment as usual during their 8-week wait period. After their wait period, participants will be enrolled in the mindfulness-based intervention.

Interventions

  • BehavioralMINDful TIME

    The intervention will include weekly 90-minute group meetings held online through Zoom. Adolescents and parents will meet in separate groups and will learn about mindfulness-based strategies that can be used to manage and reduce stress, anxiety, and depression. They will also learn evidence-based strategies to complete daily guided mindfulness meditations using Ten Percent Happier, a commercially-available mobile app. Participants will be encouraged to meditate using the mobile app for at least 10 minutes each day during and after the 8-week intervention.

06

What researchers measure

Primary outcomes

  1. Mean Change from Baseline in Children's Depression Inventory (CDI) Scores

    Parent-report measure of adolescent depressive symptoms. Scores range from 30 to 90 with higher scores indicating higher levels of depression symptoms.

    Time frame: Post-intervention (8 weeks); 2-month follow-up

  2. Mean Change from Baseline in Multidimensional Anxiety Scale for Children (MASC) Scores

    Parent-report measure of adolescent anxiety symptoms. Scores range from 30 to 90 with higher scores indicating higher levels of anxiety symptoms.

    Time frame: Post-intervention (8 weeks); 2-month follow-up

  3. Mean Change from Baseline in Child and Adolescent Mindfulness Measure (CAMM) Scores

    Adolescent-report measure of mindfulness. Scores range from 0 to 40 with higher scores indicating higher levels of mindfulness.

    Time frame: Post-intervention (8 weeks); 2-month follow-up

Secondary outcomes

  1. Mean Change from Baseline in Beck Youth Inventories (BYI) Scores

    Adolescent-report measure of depression. Scores range from 0 to 90, with higher scores indicating higher levels of depression.

    Time frame: Post-intervention (8 weeks); 2-month follow-up

  2. Mean Change from Baseline in World Health Organization-Five Wellbeing Index (WHO-5) Scores

    Adolescent-report measure on current well-being. Scores range from 0 to 100, with higher scores indicating better quality of life.

    Time frame: Post-intervention (8 weeks); 2-month follow-up

  3. Mean Change from Baseline in Adaptive Behavior Assessment System (ABAS-3) Scores

    Parent-report measure of adolescent adaptive skills across the lifespan. Scores range from 40 to 120, with higher scores indicating better adaptive skills.

    Time frame: Post-intervention (8 weeks); 2-month follow-up

  4. Mean Change from Baseline in Social Responsiveness Scale (SRS-2) Scores

    Parent-report measure of adolescent presence and severity of social impairment within autism spectrum.

    Time frame: Post-intervention (8 weeks); 2-month follow-up

  5. Mean Change from Baseline in Behavior Rating Inventory of Executive Function (BRIEF) Scores

    Parent-report measure of adolescent executive function and self-regulation. Scores range from 30 to 90, with higher scores indicating higher levels of executive dysfunction.

    Time frame: Post-intervention (8 weeks); 2-month follow-up

  6. Mean Change from Baseline in Five Facets Mindfulness Questionnaire (FFMQ) Scores

    Adolescent-report measure of mindfulness on observation, description, aware actions, non-judgmental inner experience, and non-reactivity. Factor scores range from 1 to 5, with higher scores indicating higher levels of mindfulness.

    Time frame: Post-intervention (8 weeks); 2-month follow-up

  7. Mean Change from Baseline in Family Quality of Life Scale (FQOL) Scores

    Parent-report measure of family quality of life in family interaction, parenting, emotional well-being, physical/material well-being, and disability-related support. Scores range from 1 to 5, with higher scores indicating higher satisfaction with family quality of life.

    Time frame: Post-intervention (8 weeks); 2-month follow-up

  8. Mean Change from Baseline in Stress Index for Parents of Adolescents (SIPA) Scores

    Parent-report measure of the relationship of parenting stress to adolescent characteristics, parent characteristics, the quality of the adolescent-parent interactions, and stressful life circumstances. Percentile scores range from 0 to 99, with higher scores indicating higher levels of parenting stress.

    Time frame: Post-intervention (8 weeks); 2-month follow-up

07

Study locations

1 site
  • Southwest Autism Research and Resource Center
    Phoenix, Arizona 85006, United States
08

References and documents

Individual participant data

Plan to share: Yes — All individual participant data (IPD) that underlie results in a publication will be available upon request to approved researchers.

Supporting information: Study protocol

Time frame: Data will be available upon request starting 6 months after publication and will remain available for 2 years.

Access criteria: Data requests should be submitted to Dr. Nicole Matthews at nmatthews@autismcenter.org and must include study aims and purpose and a detailed analysis plan describing how the data will be used. Requests will be reviewed by Dr. Matthews and access to the data will be made available through a secure link to download the requested data.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jan 2023 to primary completion in Jan 2024, 12 months.

Of 806 non-industry interventional studies with no phase under Autism Spectrum Disorder, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 48. This study's 12 months is below that.

Counting every sponsor, half of 829 studies reached it within 25 months; a quarter within 12 and three quarters within 47.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 5, 2023
First posted
Jan 17, 2023
StartActual
Jan 4, 2023
Primary completionActual
Jan 30, 2024
CompletionActual
Apr 8, 2024
Last update
Jul 17, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 17, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05685589
Lead sponsor
Southwest Autism Research & Resource Center
Collaborators
Arizona State University, Blue Cross Blue Shield of Arizona Foundation for Community and Health Advancement
Responsible party
Nicole Matthews, Ph.D. (Director of Research, Southwest Autism Research & Resource Center) — Principal investigator
First posted
Jan 17, 2023
Start date
Jan 4, 2023
Primary completion
Jan 30, 2024
Completion
Apr 8, 2024
Last update
Jul 17, 2024

Study contacts

Blair Braden, Ph.D
principal investigator · Arizona State University
Nicole Matthews, Ph.D
principal investigator · Southwest Autism Research and Resource Center

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion